Latest news with #TD Cowen
Reuters
13 hours ago
- Business
- Reuters
Canada's Cenovus says US refinery outlook improving, cuts 2025 production forecast
July 31 (Reuters) - Canada's Cenovus Energy ( opens new tab said on Thursday that recently completed maintenance work will improve future results from its U.S. refinery assets, as the company also lowered the upper end of its full-year oil and gas production forecast. The Calgary, Alberta-based company has struggled recently with underperformance from its U.S. refineries. But Cenovus completed a major turnaround at its Toledo, Ohio, refinery in the second quarter, 11 days ahead of schedule, and said it anticipates being able to drive down costs there and at its other refining assets. "We think there's probably another $2 per barrel that we can get out of our U.S. refining assets through time," said CEO Jon McKenzie on a conference call to discuss second-quarter results. Analysts described Cenovus' results as positive thanks to the company's improved refinery performance and outlook, despite its lower oil and gas output forecast. TD Cowen said in a note to clients that the company's 58% share of market capture in its U.S. refinery division was significantly better than expected. Cenovus is now forecasting its 2025 upstream production will be between 805,000 barrels of oil equivalent per day and 825,000 boepd, compared with 805,000 to 845,000 boepd projected previously, because of the temporary shut-in of its Rush Lake thermal facility in west-central Saskatchewan. A casing failure in an injection well in early May led to a steam release at Rush Lake, and the facility remains shut down. For the second quarter, Cenovus' total upstream production was 765,900 boepd, down from 800,800 boepd a year earlier. Wildfires in Alberta disrupted the company's operations, prompting Cenovus to temporarily shut down and evacuate its Christina Lake oil sands site and resulting in the loss of 2 million barrels of production during the quarter. The company's share price jumped as much as 4.2% in early trade before settling back to last trade at C$20.95, a 0.08% increase on the day. Cenovus' name has been floated by analysts and in media reports as a possible white-knight buyer for rival oil sands producer MEG Energy ( opens new tab, which is the subject of a hostile takeover attempt by Strathcona Resources ( opens new tab. McKenzie declined to comment on the matter on Thursday. He said the company likes its existing asset portfolio and sees no holes in it. Cenovus posted a net income of C$851 million ($614.57 million), or 45 Canadian cents per share, during the three months ended June 30, compared with C$1.0 billion, or 53 Canadian cents per share, a year earlier. ($1 = 1.3847 Canadian dollars)
Globe and Mail
a day ago
- Business
- Globe and Mail
Analysts Offer Insights on Consumer Cyclical Companies: Starbucks (SBUX) and Camping World Holdings (CWH)
Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Starbucks (SBUX – Research Report) and Camping World Holdings (CWH – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Starbucks (SBUX) In a report released yesterday, Andrew Charles from TD Cowen maintained a Hold rating on Starbucks, with a price target of $95.00. The company's shares closed last Tuesday at $92.96. According to Charles is a 5-star analyst with an average return of 9.1% and a 54.2% success rate. Charles covers the NA sector, focusing on stocks such as Restaurant Brands International, First Watch Restaurant Group, and Darden Restaurants. ;'> The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Starbucks with a $96.29 average price target, which is a 3.3% upside from current levels. In a report issued on July 14, Citi also maintained a Hold rating on the stock with a $100.00 price target. Camping World Holdings (CWH) Roth MKM analyst Scott Stember reiterated a Buy rating on Camping World Holdings yesterday and set a price target of $18.00. The company's shares closed last Tuesday at $17.64. According to Stember is a 4-star analyst with an average return of 8.8% and a 56.9% success rate. Stember covers the NA sector, focusing on stocks such as Standard Motor Products, Winnebago Industries, and Fox Factory Holding. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Camping World Holdings with a $21.33 average price target.
Yahoo
a day ago
- Business
- Yahoo
Prime Medicine Announces Pricing of Public Offering
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. TD Cowen and BMO Capital Markets are acting as joint book-running managers for the offering. The shares of common stock are being offered by Prime Medicine pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine's beliefs and expectations regarding: the timing and closing of the public offering. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Prime Medicine's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine's views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor and Media Contacts Gregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
4 days ago
- Business
- Yahoo
TD Cowen Initiates Coverage on Norwegian Cruise Line Holdings Ltd. (NCLH) with $31 PT ; BofA Raises PT to $27
Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) is included in our list of the . A busy airport terminal full of travelers eager to utilize the company's services. With cruise stocks gaining momentum, Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) is drawing analyst attention as they reassess the sector's long-term potential and short-term momentum. On July 22, 2025, TD Cowen gave a 'Buy' rating on Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) with a $31 price target. Within the travel sector, the analyst considered NCLH an underappreciated gainer. With a 7% annual industry revenue growth projected through 2029, the analyst believes the company, trading at an airline-level valuation multiple, holds upside potential. Meanwhile, on July 23, 2025, BofA increased its price target on Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) from $20 to $27, maintaining a 'Neutral' rating. The analyst cited the cruise sector's 72% gain since the market bottom in April and thus, expects strong earnings. With its Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas brands, Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) offers luxury travel experiences across all major global destinations. It is included in our list of cheap travel stocks. While we acknowledge the potential of NCLH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
TD Cowen and BofA Bullish on Carnival Corporation & plc (CCL) Amid Strong Travel Momentum
Carnival Corporation & plc (NYSE:CCL), considered a cheaply priced stock and a top pick among analysts, is included in our list of the . A bustling airport terminal with travelers heading to their dream destination. As the travel industry's momentum is on an upward trajectory, Carnival Corporation & plc (NYSE:CCL) is attracting the attention of Wall Street. On July 22, 2025, citing the company's disciplined capacity growth, TD Cowen gave Carnival Corporation & plc (NYSE:CCL) a 'Buy' rating with a $36 price target. Instead of scaling up, the company is focusing on yield optimization with the help of its proprietary YODA system. The system resulted in an industry-leading 7% yield growth in the first half of 2025 with a strong gross margin of 54.7%. The analyst expects a five-year CAGR of 19% in net income and 21% in EPS due to this focus on margins and declining interest expenses. Furthermore, on July 23, 2025, BofA increased its price target on Carnival Corporation & plc (NYSE:CCL) from $31 to $38. The analyst, too, cited the growing momentum of cruise equities, along with strong earnings expectations. Carnival Corporation & plc (NYSE:CCL), a leisure travel company, offers cruise vacations with brands like Carnival Cruise Line, Princess Cruises, and Holland America Line. It is included in our list of cheap travel stocks. While we acknowledge the potential of CCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
